<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725072</url>
  </required_header>
  <id_info>
    <org_study_id>MS200527_0075</org_study_id>
    <secondary_id>2018-003371-35</secondary_id>
    <nct_id>NCT03725072</nct_id>
  </id_info>
  <brief_title>Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib</brief_title>
  <official_title>Phase I, Open Label, Single Dose Study to Determine the Pharmacokinetics, Metabolism, and Excretion of [14C]-Evobrutinib in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the absorption, metabolism, and excretion of
      [14C]-evobrutinib in healthy participants
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Radioactivity Recovery Rate of Evobrutinib, Total Radioactivity and its Metabolites</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Excretion of Evobrutinib, Total Radioactivity and its Metabolites in Urine and Feces</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance of Evobrutinib, Total Radioactivity and its Metabolites</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Total [14C] Radioactivity (Evobrutinib and Metabolites)</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Total [14C] Radioactivity (Evobrutinib and Metabolites)</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of Total [14C] Radioactivity (Evobrutinib and Metabolites)</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Total [14C] Radioactivity (Evobrutinib and Metabolites)</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/f) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Clearance (CL/f) of Evobrutinib</measure>
    <time_frame>Pre-dose up to Day 35 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings</measure>
    <time_frame>From time of first dose to end of study participation approximately at Day 37</time_frame>
    <description>Number of participants with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment -emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>From time of first dose to end of study participation approximately at Day 37</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment -emergent Adverse Events (TEAEs) and Serious TEAEs by Severity</measure>
    <time_frame>From time of first dose to end of study participation approximately at Day 37</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Evobrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evobrutinib</intervention_name>
    <description>Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain [14C]-evobrutinib.</description>
    <arm_group_label>Evobrutinib</arm_group_label>
    <other_name>M2951</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are overtly healthy as determined by medical evaluation, including
             medical history, physical examination, laboratory tests, and cardiac monitoring

          -  Have a body weight within 50.0 to 120.0 kilogram (kg) (inclusive) and body mass index
             within the range 19.0 - 30.0 kilogram per meter square (kg/m^2) (inclusive)

          -  Male participants agree to be consistent with local regulations on contraception
             methods

          -  Can give signed informed consent

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  History or presence of clinically relevant respiratory, gastrointestinal, renal,
             hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,
             musculoskeletal, genitourinary, immunological, dermatological, connective tissue
             diseases or disorders

          -  Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery

          -  Any surgical or medical condition which might significantly alter the ADME of drugs

          -  History of any malignancy, chronic or recurrent acute infection

          -  History of shingles

          -  History of drug hypersensitivity ascertained or presumptive allergy/hypersensitivity
             to the active drug substance and/or formulation ingredients

          -  History of alcoholism or drug abuse

          -  History of residential exposure to tuberculosis, or a positive QuantiFERON test at
             screening

          -  Administration of live vaccines or live-attenuated virus vaccines

          -  Any condition, including findings in the laboratory tests, medical history, or other
             screening assessments, that in the opinion of the Investigator constitutes an
             inappropriate risk or a contraindication for participation in the study or that could
             interfere with the study's objectives, conduct, or evaluation

          -  Prior/concomitant therapy

          -  Relevant radiation exposure

          -  Clinically relevant findings (excluding minor deviations) in biochemistry, hematology,
             coagulation and urinalysis

          -  Vital signs (pulse rate and blood pressure) outside the normal range

          -  Estimated Glomerular Filtration rate according to the Chronic Kidney Disease
             Epidemiology Collaboration (CKD-EPI)

          -  Semi supine systolic blood pressure (SBP) greater than (&gt;) 140 millimeters of Mercury
             (mmHg) or less than (&lt;) 90 mmHg, diastolic blood pressure (DBP) &gt; 90 mmHg or &lt; 45 mmHg
             and pulse rate &gt;= 100 bpm or =&lt; 40 bpm, at admission

          -  12-Lead electrocardiogram (ECG) showing a QTcF &gt; 450 millisecond (ms), PR &gt; 215 ms, or
             QRS &gt; 120 ms

          -  Positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody, hepatitis
             C antibody, or human immunodeficiency virus (HIV) I and II tests at screening

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200527_0075</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>[14C]-evobrutinib</keyword>
  <keyword>Healthy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

